Epizyme reported $231.83M in Loan Capital for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Agios Pharmaceuticals AGIO:US $ 0M 0.17M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 33291M 4833M
Avrobio Inc AVRO:US $ 0 0
Biogen BIIB:US $ 6272.3M 996.9M
Bluebird Bio BLUE:US $ 0M 0M
Cerulean Pharma CERU:US $ 0 0
Daiichi Sankyo 4568:JP Y 143254M 20093M
Eisai 4523:JP Y 49919M 6M
Epizyme EPZM:US $ 231.83M 640K
Exelixis EXEL:US $ 0M 0M
GlaxoSmithKline GSK:LN 20736M 294M
Glaxosmithkline GSK:US $ 20736M 294M
IONIS PHARMACEUT IONS:US $ 1303M 62.3M
Karyopharm Therapeutics KPTI:US $ 301.57M 195K
Macrogenics MGNX:US $ 0 0
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 24715M 1776M
Novartis NVS:US $ 24715M 1776M
Regeneron Pharmaceuticals REGN:US $ 1979.6M 0.4M
Seattle Genetics SGEN:US $ 0M 0M
Spectrum Pharmaceuticals SPPI:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 513.26M 11.67M
Xencor XNCR:US $ 0M 0M